Fig. 4

Treatment with intravenous (tail vein) DpC (4 mg/kg/day) over 3 weeks significantly reduces orthotopic neuroblastoma tumor growth (in adrenal gland) in vivo using SK-N-LP/Luciferase xenografts in nude mice. a Upper panel mice are shown before administration via the tail vein of the vehicle control (Con) or DpC (Day 0), while the lower panel represents mice treated intravenously (tail vein) with either DpC (4 mg/kg/day) or the vehicle control daily for 3 weeks (i.e., Day 21). b DpC-treated tumors had significantly (p < 0.05) lower region of interest (ROI) change rates when compared to vehicle control tumors. c Neuroblastoma xenografts significantly decreased in volume after the DpC treatment in (a). d Body weight change (%) of mice treated with the control (vehicle) or DpC (4 mg/kg/day) over 3 weeks. *p < 0.05 by an unpaired two-tailed t test. The results are presented as mean ± SEM (n = 4)